CTOs on the Move

Ultragenyx Pharmaceutical

www.ultragenyx.com

 
Ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. Our company is led by an experienced management team in rare disease therapeutics. Recognizing that our primary responsibility is to our patients, we are working with advocacy ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Mohit Arora
Executive Director, IT Infrastructure & Cybersecurity Profile
Alex de Alvarez
Director, Global Security Profile
Ryan Bonistalli
Compliance Director Profile

Similar Companies

EMD Biosciences

EMD Biosciences, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmacists Mutual Companies

Pharmacists Mutual Companies is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Avantra Biosciences FKA Decision Biomarkers

Avantra Biosciences FKA Decision Biomarkers, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Imara

Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.

Abpro

We are a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases.